← Leaderboards
Devanand Sarkar
Virginia Commonwealth University
$13,330,601
Attributed
$16,849,134
Total exposure
15
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.6M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,174,281 · 16
By mechanism
R01$12,607,766 · 5
P01$6,623,254 · 3
R61$1,179,675 · 1
P30$574,732 · 2
R21$364,857 · 1
R25$323,951 · 1
Top collaborators
- Paul B Fisher9 shared
- Xiang-Yang Wang5 shared
- Joyce A Lloyd2 shared
- Maghboeba Mosavel2 shared
- Gretchen N Neigh2 shared
- Mohamad Imad Damaj1 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Paul B Fisher$21,846,479
- Joseph William Landry$2,951,878
- Swadesh K Das$413,809
- Joyce A Lloyd$10,055,109
- Sumit Saha$45,660
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularPlayMalignant NeoplasmsPrimary Carcinoma Of The Liver CellsGenesMouse ModelProteinsHepatocyteOverexpressionPathogenesisSmall Interfering RnaEffective TherapyTreatment EfficacyTargeted TreatmentClinical TrialsMalignant Epithelial CellMediatingNanoparticle DeliverySignal TransductionInnovationTransgenic MiceGrowthAstrocytesMonitor
Grant awards (62)
ExpLoiting thErapeutic VulnerAbilities in hepaTocEllular carcinoma (ELEVATE)$2,646,688
P01 · FY2025 · CA · contact PI
The role of AEG-1 in NASH and NASH-HCC$543,969
R01 · FY2025 · DK · contact PI
Cooperation of Co-Amplified Genes in Hepatocellular Carcinoma$517,389
P01 · FY2025 · CA · contact PI
Cancer Research Training and Education Coordination (CRTEC)$243,488
P30 · FY2025 · CA · contact PI
CTSA Predoctoral T32 at Virginia Commonwealth University$197,004
T32 · FY2025 · TR · contact PI
Administrative Core$122,684
P01 · FY2025 · CA · contact PI
The role of AEG-1 in NASH and NASH-HCC$41,044
R01 · FY2025 · DK · contact PI
ExpLoiting thErapeutic VulnerAbilities in hepaTocEllular carcinoma (ELEVATE)$2,678,459
P01 · FY2024 · CA · contact PI
The role of AEG-1 in NASH and NASH-HCC$577,461
R01 · FY2024 · DK · contact PI
Cooperation of Co-Amplified Genes in Hepatocellular Carcinoma$545,014
P01 · FY2024 · CA · contact PI
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma$392,721
R01 · FY2024 · CA · contact PI
Administrative Core$113,020
P01 · FY2024 · CA · contact PI
CTSA Predoctoral T32 at Virginia Commonwealth University$98,546
T32 · FY2024 · TR · contact PI
The role of AEG-1 in NASH and NASH-HCC$70,363
R01 · FY2024 · DK · contact PI
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma$61,505
R01 · FY2024 · CA · contact PI
Cancer Research Training and Education Coordination (CRTEC)$55,156
P30 · FY2024 · CA · contact PI
The role of AEG-1 in NASH and NASH-HCC$598,687
R01 · FY2023 · DK · contact PI
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma$494,436
R01 · FY2023 · CA · contact PI
A novel role of IGFBP7 in the microenvironment of hepatocellular carcinoma$476,580
R01 · FY2023 · CA · contact PI
Targeting oncogenes for hepatocellular carcinoma$387,682
R01 · FY2023 · CA · contact PI
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma$128,086
R01 · FY2023 · CA · contact PI
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma$66,972
R01 · FY2023 · CA · contact PI
Cancer Research Training and Education Coordination (CRTEC)$55,156
P30 · FY2023 · CA · contact PI
Pilot Project 1 (Liver Cancer)$53,329
P20 · FY2023 · CA · contact PI
The role of AEG-1 in NASH and NASH-HCC$29,319
R01 · FY2023 · DK · contact PI
Initial Development of AEG-1 inactivation as a possible strategy for pain treatment$1,179,675
R61 · FY2022 · NS
The role of AEG-1 in NASH and NASH-HCC$623,536
R01 · FY2022 · DK · contact PI
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma$494,436
R01 · FY2022 · CA · contact PI
A novel role of IGFBP7 in the microenvironment of hepatocellular carcinoma$476,580
R01 · FY2022 · CA · contact PI
Targeting oncogenes for hepatocellular carcinoma$387,682
R01 · FY2022 · CA · contact PI
Pilot Project 1 (Liver Cancer)$66,267
P20 · FY2022 · CA · contact PI
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma$52,578
R01 · FY2022 · CA · contact PI
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma$504,528
R01 · FY2021 · CA · contact PI
A novel role of IGFBP7 in the microenvironment of hepatocellular carcinoma$486,305
R01 · FY2021 · CA · contact PI
Targeting oncogenes for hepatocellular carcinoma$396,280
R01 · FY2021 · CA · contact PI
Preparing cancer researchers with a 21st century skill set$161,977
R25 · FY2021 · CA · contact PI
Pilot Project 1 (Liver Cancer)$84,900
P20 · FY2021 · CA · contact PI
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma$518,339
R01 · FY2020 · CA · contact PI
A novel role of IGFBP7 in the microenvironment of hepatocellular carcinoma$486,305
R01 · FY2020 · CA · contact PI
Targeting oncogenes for hepatocellular carcinoma$402,127
R01 · FY2020 · CA · contact PI
Preparing cancer researchers with a 21st century skill set$161,974
R25 · FY2020 · CA · contact PI
A novel role of IGFBP7 in the microenvironment of hepatocellular carcinoma$500,003
R01 · FY2019 · CA · contact PI
Targeting oncogenes for hepatocellular carcinoma$415,877
R01 · FY2019 · CA · contact PI
The role of AEG-1 in NASH and NASH-HCC$342,705
R01 · FY2019 · DK · contact PI
The role of AEG-1 in NASH and NASH-HCC$342,853
R01 · FY2018 · DK · contact PI
The role of AEG-1 in NASH and NASH-HCC$346,488
R01 · FY2017 · DK · contact PI
The role of AEG-1 in NASH and NASH-HCC$363,258
R01 · FY2016 · DK · contact PI
A novel mediator of obesity associated hepatocellular carcinoma (HCC)$165,844
R21 · FY2015 · CA · contact PI
Analysis of a novel regulator of hepatocellular carcinoma$291,880
R01 · FY2014 · CA · contact PI
A novel mediator of obesity associated hepatocellular carcinoma (HCC)$199,013
R21 · FY2014 · CA · contact PI
Analysis of a novel regulator of hepatocellular carcinoma$282,853
R01 · FY2013 · CA · contact PI
Analysis of a novel regulator of hepatocellular carcinoma$8,260
R01 · FY2013 · CA · contact PI
Analysis of a novel regulator of hepatocellular carcinoma$300,907
R01 · FY2012 · CA · contact PI
Analysis of a novel regulator of hepatocellular carcinoma$56,355
R01 · FY2012 · CA · contact PI
Analysis of a novel regulator of hepatocellular carcinoma$300,907
R01 · FY2011 · CA · contact PI
Analysis of a novel regulator of hepatocellular carcinoma$47,686
R01 · FY2011 · CA · contact PI
Analysis of a novel regulator of hepatocellular carcinoma$310,213
R01 · FY2010 · CA · contact PI
mda-9/svntenin: A Novel Diagnostic Marker and a Therapeutic Target for Metastatic$49,883
P30 · FY2010 · AR · contact PI
mda-9/svntenin: A Novel Diagnostic Marker and a Therapeutic Target for Metastatic$49,883
P30 · FY2009 · AR · contact PI
mda-9/svntenin: A Novel Diagnostic Marker and a Therapeutic Target for Metastatic$49,883
P30 · FY2008 · AR · contact PI
mda-9/svntenin: A Novel Diagnostic Marker and a Therapeutic Target for Metastatic$39,083
P30 · FY2007 · AR · contact PI
mda-9/svntenin: A Novel Diagnostic Marker and a Therapeutic Target for Metastatic$32,200
P30 · FY2006 · AR · contact PI